Oyster Point Pharma, Inc.
Acquired
Matched to this startup by its exact name; the buyer's report is the source.
| Acquired | Buyer | Acquisition date | Completion | Price | Stake | Source |
|---|---|---|---|---|---|---|
| Oyster Point Pharma, Inc | Viatris Inc. | 2023 | — | $427 M | — | Annual report |
Funding rounds
2 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Feb 2019 | $85 M | No. 2 | $50 to $250 million | equity | SEC | |
| Oct 2017 | $29 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Oyster Point Pharma, Inc. chose not to state its revenue in its newest notice of a funding round (Feb 2019).
SEC Form D · Feb 2019
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Feb 2019
That is all the official record says: Oyster Point Pharma, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
30 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Falcon Vision LLC | Other | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| InvOpps GP IV, L.L.C. | Other | not stated | not stated | Held Series B preferred stock, 10% owner, director (Form 3, 2019) | SEC Form 3 |
| InvOpps IV, L.P. | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner, director (Form 3, 2019) | SEC Form 3 |
| InvOpps IV US, L.P. | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner, director (Form 3, 2019) | SEC Form 3 |
| KKR Associates HCSG L.P. | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| KKR & Co. L.P. | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| KKR Fund Holdings GP Ltd | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| KKR Fund Holdings L.P. | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| KKR Group Holdings Corp. | Company | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| KKR Hcsg GP LLC | Other | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| KKR Healthcare Strategic Growth Fund L.P. | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| KKR Management LLC | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Kleiner Perkins Caufield & Byers XIV, LLC | Other | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| KPCB XIV Associates, LLC | Other | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| KPCB XIV Founders Fund, LLC | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Mark Anthony Murray | Person | not stated | not stated | Held Series A preferred stock, director (Form 3, 2019) | SEC Form 3 |
| Nea 14 GP, LTD | Company | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| NEA Partners 14, L.P. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| New Enterprise Associates 14, L.P. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Oyster Point Pharma I, LLC | Other | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Versant Side Fund IV, L.P. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Versant Vantage I GP-GP, LLC | Other | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Versant Vantage I GP, L.P. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Versant Vantage I, L.P. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Versant Venture Capital IV, L.P. | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Versant Venture Capital VI, L.P. | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Versant Ventures IV, LLC | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Versant Ventures VI GP-GP, LLC | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Versant Ventures VI GP, L.P. | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Vida Ventures, LLC | Venture capital | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 8 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Jeffrey A. Nau | Executive officer | Feb 2019 |
| Mark A. Murray | Executive officer | Feb 2019 |
| Ali J Behbahani | Director | Feb 2019 |
| Benjamin A. Tsai | Director | Feb 2019 |
| Clare A. Ozawa | Director | Feb 2019 |
| D. Michael Ackermann | Director | Feb 2019 |
| Jeffrey A. Nau | Director | Feb 2019 |
| Mark A. Murray | Director | Feb 2019 |
| William J Link | Director | Feb 2019 |
Acquired (Jan 1, 2023). Acquired by Viatris Inc..